A Nationwide Survey of mRNA COVID-19 Vaccinee's Experiences on Adverse Events and Its Associated Factorsopen access
- Authors
- Yoon, Dongwon; Jeon, Ha -Lim; Noh, Yunha; Choe, Young June; Choe, Seung-Ah; Jung, Jaehun; Shin, Ju-Young
- Issue Date
- Jun-2023
- Publisher
- KOREAN ACAD MEDICAL SCIENCES
- Keywords
- COVID-19 Vaccines; Drug-Related Side Effects and Adverse Reactions; mRNA Vaccines; Risk Factors; Survey and Questionnaires
- Citation
- JOURNAL OF KOREAN MEDICAL SCIENCE, v.38, no.22, pp.1 - 14
- Journal Title
- JOURNAL OF KOREAN MEDICAL SCIENCE
- Volume
- 38
- Number
- 22
- Start Page
- 1
- End Page
- 14
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/88467
- DOI
- 10.3346/jkms.2023.38.e170
- ISSN
- 1011-8934
- Abstract
- Background: Although coronavirus disease 2019 (COVID-19) vaccines have been distributed worldwide under emergency use authorization, the real-world safety profiles of mRNA vaccines still need to be clearly defined. We aimed to identify the overall incidence and factors associated with adverse events (AEs) following mRNA COVID-19 vaccination. Methods: We conducted web-based survey from December 2 to 10 in 2021 with a 2,849 nationwide sampled panel. Study participants were individuals who had elapsed at least two -weeks after completing two dosing schedules of COVID-19 vaccination aged between 18-49 years. We weighted the participants to represent the Korean population. The outcome was the overall incidence of AEs following mRNA COVID-19 vaccination and associated factors. We estimated the weighted odds ratios (ORs) using multivariable logistic regression models to identify the factors associated with AEs. Results: Of the 2,849 participants (median [interquartile range] age, 35 [27-42] years; 51.6% male), 90.8% (n = 2,582) for the first dose and 88.7% (n = 2,849) for the second dose reported AEs, and 3.3% and 4.3% reported severe AEs, respectively. Occurrence of AEs was more prevalent in mRNA-1273 (OR, 2.06; 95% confidence interval [CI], 1.59-2.67 vs. BNT162b2), female sex (1.88; 1.52-2.32), and those with dermatologic diseases (2.51; 1.32-4.77). History of serious allergic reactions (1.96; 1.06-3.64) and anticoagulant medication use (4.72; 1.92-11.6) were associated with severe AEs. Conclusion: Approximately 90% of participants reported AEs following mRNA COVID-19 vaccination. Substantial factors, including vaccine type (mRNA-1273), female sex, and dermatologic diseases were associated with AEs. Our findings could aid policymakers in establishing vaccination strategies tailored to those potentially susceptible to AEs.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의예과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/88467)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.